Gadodiamide contrast agent 'activates' fibroblasts: A possible cause of nephrogenic systemic fibrosis

Journal of Pathology

Volumn 214, Issue 5, 2008, Pages 584-593

  Edward, M ^a   Quinn, J A ^a   Mukherjee, S ^b   Jensen, M B V ^a   Jardine, A G ^a   Mark, P B ^a   Burden, A D ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Collagen; Fibroblasts; Gadodiamide; Hyaluronan; Nephrogenic systemic fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; GADODIAMIDE; HYALURONIC ACID;

ADULT; AGED; ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; FIBROBLAST; HEMODIALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY FIBROSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY;

ADULT; AGED; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; FIBROBLASTS; FIBROSIS; GADOLINIUM DTPA; HUMANS; HYALURONIC ACID; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; MOLECULAR WEIGHT; SKIN;

EID: 41649098148     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2311     Document Type: Article

References (41)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxedema-like cutaneous disease in renal-dialysis patients. Lancet 2000;356:1000-1001.
2. McNeill AM, Barr PJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Br J Dermatol 2002;41:364-367.
3. Neudecker BA, Stern R, Mark LA, Steinberg S. Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol 2005;32:612-615.
4. Cowper SE, Bucala R, LeBoit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis - setting the record straight. Semin Arthritis Rheum 2006;35:208-210.
5. Quan TE, Cowper S, Wu S-P, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004;36:598-606.
6. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 2004;150:1050-1052.
7. Bucala R, Spegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994;1:71-81.
8. Chesney J, Bucala R. Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr Rheumatol Rep 2000;2:501-505.
9. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003;25:358.
10. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
11. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16:2619-2621.
12. Kuo PH, Kanal E, Abu-Alfa AK, Cowper S. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647- 649.
13. Edward M, Fitzgerald L, Thind C, Leman J, Burden AD. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol 2007;156:473-479.
14. Amjad SB, Carachi R, Edward M. Keratinocyte regulation of TGF-β and connective tissue growth factor expression: a role in suppression of scar tissue formation. Wound Rep Reg 2007;15:748-755.
15. Meran S, Thomas D, Stephens P, Martin J, Bowen T, Phillips A, et al. Involvement of hyaluronan in regulation of fibroblast phenotype. J Biol Chem 2007;282:25687-25697.
16. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007;127:526-537.
17. Chesney J, Bucala R. Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr Rheum Rep 2000;2:501-505.
18. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004;36:598-606.
19. Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Fibrocytes from burn patients regulate the activity of fibroblasts. Wound Rep Reg 2007;15:113-121.
20. Chaudhuri V, Zhou L, Karasek MA. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: a potential role in skin fibrogenesis. J Cutan Pathol 2007;34:146-153.
21. Harrison CA, Gossiel F, Bullock AJ, Sun T, Blumsohn A, MacNeil S. Investigation of keratinocyte regulation of collagen I synthesis by dermal fibroblasts in a simple in vitro model. Br J Dermatol 2006;154:401-410.
22. Coleman PJ. Evidence for a role of hyaluronan in the spacing of fibrils within collagen bundles in rabbit synovium. Biochim Biophys Acta 2002;1571:173-182.
23. Greisberg JK, Wolf JM, Wyman J, Zou L, Terek RM. Gadolinium inhibits thymidine incorporation and induces apoptosis in chondrocytes. J Orthop Res 2001;19:797-801.
24. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
25. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
26. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
27. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007;188:586-592.
28. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42:139-145.
29. Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997;25:245-255.
30. Behra-Miellet J, Gressier B, Brunet C, Dine C, Luyckx M, Cazin M, et al. Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 1996;18:437-442.
31. Mann JS. Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 1993;17:S19-S23.
32. Vorobiov M, Basok A, Tovbin D, Shnaider A, Katchko L, Rogachev B. Iron-mobilising properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003;18:884- 887.
33. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171:380-389.
34. Stemvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329-337.
35. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157.
36. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790.
37. Swaminathan S, Leung N. Nephrogenic fibrosing dermopathy: lessons from the past. Int J Dermatol 2006;45:639-641.
38. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48:55-60.
39. Karasek MA. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? Med Hypothesis 2007;68:650-655.
40. Wu W-S, Wang F-S, Yang KD, Huang CC, Kuo Y-R. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol 2006;126:1264-1271.
41. Distler JHW, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-322.